Zai Lab Limited (NASDAQ:ZLAB – Get Free Report) insider Frazor Titus Edmondson III sold 885 shares of Zai Lab stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $16.15, for a total value of $14,292.75. Following the completion of the transaction, the insider now owns 22,621 shares of the company’s stock, valued at $365,329.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Zai Lab Trading Down 0.9 %
ZLAB opened at $15.90 on Thursday. The stock has a 50-day moving average price of $19.44 and a 200-day moving average price of $23.68. Zai Lab Limited has a 12-month low of $15.53 and a 12-month high of $40.42.
Zai Lab (NASDAQ:ZLAB – Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.11). The company had revenue of $65.83 million for the quarter, compared to analysts’ expectations of $70.41 million. Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. On average, research analysts anticipate that Zai Lab Limited will post -3.1 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on ZLAB
Institutional Investors Weigh In On Zai Lab
Several institutional investors have recently bought and sold shares of the stock. Invesco Ltd. boosted its holdings in Zai Lab by 13.9% during the 1st quarter. Invesco Ltd. now owns 8,258,118 shares of the company’s stock valued at $363,192,000 after acquiring an additional 1,006,575 shares during the period. Wellington Management Group LLP raised its position in Zai Lab by 177.6% during the 4th quarter. Wellington Management Group LLP now owns 5,336,457 shares of the company’s stock valued at $145,845,000 after purchasing an additional 3,413,829 shares during the last quarter. BlackRock Inc. raised its position in Zai Lab by 1.9% during the 1st quarter. BlackRock Inc. now owns 4,381,747 shares of the company’s stock valued at $145,737,000 after purchasing an additional 80,310 shares during the last quarter. Vanguard Group Inc. raised its position in Zai Lab by 54.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,553,080 shares of the company’s stock valued at $121,515,000 after purchasing an additional 1,258,009 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Zai Lab by 62.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,409,373 shares of the company’s stock valued at $80,136,000 after purchasing an additional 923,108 shares during the last quarter. 41.65% of the stock is currently owned by hedge funds and other institutional investors.
Zai Lab Company Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Further Reading
- Five stocks we like better than Zai Lab
- What is Put Option Volume?
- Gold Rush: Exploring 5 Sector Giants Amidst Soaring Prices
- What Is Dividend Yield and How Do You Calculate It?
- What is a Bull Market? Key Information about Bull Markets
- Best Stocks Under $5.00
- Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.